Product image of Myoview (Tetrofosmin) supplied by GNH India

Myoview

Active Ingredient:
Tetrofosmin
Origin:
EU

Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is employed in myocardial perfusion imaging to assess coronary artery disease in adult patients, enabling visualization of myocardial blood flow during single‑photon emission computed tomography (SPECT) scans and assisting clinicians in evaluating cardiac function and ischemia.

GNH India supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company provides reliable sourcing, regulatory support and global logistics to meet the needs of cardiac imaging centres.

Manufacturer / TM Owner

Ge Healthcare Sas

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Myoview (technetium‑99m tetrofosmin) is used in cardiac imaging to evaluate myocardial perfusion.
  • Myocardial perfusion imaging: provides images of blood flow to the heart muscle to detect perfusion defects.
  • Coronary artery disease evaluation: helps identify areas of reduced blood flow due to arterial blockages.
  • Ischemic heart disease assessment: assists in diagnosing ischemia during stress testing.

How It Works

  • Technetium‑99m tetrofosmin is a lipophilic cationic complex that readily crosses cell membranes and accumulates in myocardial cells in proportion to regional blood flow. After intravenous injection, the technetium‑99m radioisotope emits gamma photons detectable by SPECT cameras, allowing visualization of perfusion patterns and identification of areas with reduced circulation. The tracer’s rapid uptake and stable myocardial retention provide high‑quality images within minutes, while rapid renal clearance reduces background activity.

Side Effects

Adverse reactions to Myoview are generally infrequent but may occur following intravenous administration.

Common Side Effects

  • Injection site pain: mild discomfort at the site of administration.
  • Nausea: transient feeling of queasiness.
  • Headache: mild to moderate headache that may last for a short period.
  • Dizziness: temporary light‑headedness experienced shortly after injection.

Serious or Rare Side Effects

  • Allergic reaction: urticaria, bronchospasm, or anaphylaxis requiring immediate medical attention.
  • Hypotension: significant drop in blood pressure that may cause faintness.
  • Arrhythmia: new onset cardiac rhythm disturbances observed during monitoring.

Precautions & Warnings

  • When using Myoview, clinicians should observe specific precautions to ensure patient safety and optimal image quality.
  • Patient selection: verify indication and assess renal function before administration.
  • Allergy assessment: inquire about prior reactions to radiopharmaceuticals or technetium compounds.
  • Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited.
  • Concurrent medications: consider potential interference with thyroid uptake agents.
  • Hydration: encourage adequate fluid intake to facilitate renal clearance of the tracer.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Myoview may interact with other agents that affect thyroid function or radiotracer distribution.

Major Interactions (Avoid)

  • Iodine‑containing contrast agents: can block myocardial uptake of technetium‑99m tracers.
  • Thyroid hormone therapy: may alter tracer biodistribution.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may influence heart rate and affect stress test results.
  • Calcium channel blockers: can modify myocardial blood flow during imaging.
  • Vasodilators (e.g., dipyridamole): may enhance tracer uptake and require protocol adjustment.

Frequently Asked Questions

Myoview is a radiopharmaceutical used primarily for myocardial perfusion imaging. It helps visualize blood flow to the heart muscle during SPECT scans, allowing clinicians to assess coronary artery disease, detect ischemic regions, and evaluate overall cardiac function.

Tetrofosmin, labeled with technetium‑99m, is a lipophilic cation that readily enters myocardial cells. Its uptake is proportional to regional blood flow, so areas with good perfusion accumulate more tracer, while poorly perfused zones show reduced activity, which can be captured by gamma‑camera imaging.

The administered activity of Myoview is determined by the prescribing physician based on the imaging protocol, patient weight, and equipment specifications. Dosage is individualized and should follow local regulatory guidelines and the manufacturer’s prescribing information.

Safety data for Myoview in pregnant or lactating women are limited. It should be used only if the potential diagnostic benefit justifies any potential risk to the fetus or infant, and alternative non‑radiopharmaceutical methods should be considered whenever possible.

To order Myoview, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

The primary alternative to Myoview is technetium‑99m sestamibi, another myocardial perfusion tracer. Both provide high‑quality SPECT images, but tetrofosmin generally offers faster liver clearance, potentially reducing image artefacts. Choice often depends on institutional preference, availability, and specific protocol requirements.

Myoview must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. The vial should be kept in its original packaging until use, and any unused portion should be discarded according to local radiopharmaceutical waste regulations.

Myoview is administered as an intravenous injection by a qualified healthcare professional. The solution is injected into a peripheral vein, typically followed by a short waiting period before image acquisition to allow adequate myocardial uptake of the tracer.

The most serious risks include severe allergic reactions such as anaphylaxis, significant hypotension, and cardiac arrhythmias. Patients should be monitored closely during and after administration, and emergency equipment should be readily available to manage any acute adverse events.

Myoview should be avoided in patients with known hypersensitivity to tetrofosmin, technetium‑99m compounds, or any component of the formulation. It is also contraindicated in individuals where the diagnostic benefit does not outweigh potential radiation exposure, such as certain pregnant women or those unable to undergo SPECT imaging.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tetrofosmin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT